Literature DB >> 27797367

Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study.

R F Duarte1, I Sánchez-Ortega1, M Arnan1, B Patiño1, J Ayats2, A Sureda1, M Cuenca-Estrella3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27797367     DOI： 10.1038/bmt.2016.279

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

Review 2.  Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

Authors:  Eyal Robenshtok; Anat Gafter-Gvili; Elad Goldberg; Miriam Weinberger; Moshe Yeshurun; Leonard Leibovici; Mical Paul
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

3.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

Authors:  Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

4.  Galactomannan detection and diagnosis of invasive aspergillosis.

Authors:  J Peter Donnelly; Mariske M Leeflang
Journal:  Clin Infect Dis       Date:  2010-04-01       Impact factor: 9.079

5.  Selection and interpretation of diagnostic tests and procedures. Principles and applications.

Authors:  P F Griner; R J Mayewski; A I Mushlin; P Greenland
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

6.  Design issues in studies evaluating diagnostic tests for aspergillosis.

Authors:  Kieren A Marr; Wendy Leisenring
Journal:  Clin Infect Dis       Date:  2005-09-15       Impact factor: 9.079

7.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

Authors:  Catherine Cordonnier; Cécile Pautas; Sébastien Maury; Anne Vekhoff; Hassan Farhat; Felipe Suarez; Nathalie Dhédin; Francoise Isnard; Lionel Ades; Frédérique Kuhnowski; Françoise Foulet; Mathieu Kuentz; Patrick Maison; Stéphane Bretagne; Michaël Schwarzinger
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

8.  Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study.

Authors:  Corrado Girmenia; Alessandra Micozzi; Giuseppe Gentile; Stefania Santilli; Eva Arleo; Luisa Cardarelli; Saveria Capria; Clara Minotti; Claudio Cartoni; Simonetta Brocchieri; Vito Guerrisi; Giovanna Meloni; Robin Foà; Pietro Martino
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Galactomannan testing during mold-active prophylaxis.

Authors:  Oliver A Cornely
Journal:  Clin Infect Dis       Date:  2014-08-27       Impact factor: 9.079
View more
  2 in total

1.  Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.

Authors:  Claire Calmettes; Frederic Gabriel; Elodie Blanchard; Vincent Servant; Stéphane Bouchet; Nathanael Kabore; Edouard Forcade; Camille Leroyer; Audrey Bidet; Valérie Latrabe; Thibaut Leguay; Stephane Vigouroux; Reza Tabrizi; Dominique Breilh; Isabelle Accoceberry; Manuel Tunon de Lara; Arnaud Pigneux; Noel Milpied; Pierre-Yves Dumas
Journal:  Oncotarget       Date:  2018-06-01

2.  Biomarkers of fungal infection: Expert opinion on the current situation.

Authors:  E Bouza; B Almirante; J García Rodríguez; J Garnacho-Montero; M Salavert; P Muñoz; M Sanguinetti
Journal:  Rev Esp Quimioter       Date:  2019-11-14       Impact factor: 1.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.